

April 7, 2021

Josh Bayliss
Chief Executive Officer
VG Acquisition Corp.
65 Bleecker Street, 6th Floor
New York, NY 10012

Re: VG Acquisition
Registration
Filed March 26,
File No. 333-254772

Corp.
Statement on Form S-4
2021

Dear Mr. Bayliss:

We have reviewed your registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments.

Registration Statement on Form S-4, Filed March 26, 2021

What are the U.S. federal income tax consequences of the Domestication Proposal, page xix

1. We note your response to comment 1. Please revise to delete the phrase "Assuming that the Domestication so qualifies..." Additionally, revise the "Effects of the Domestication" discussion on page 159 to specifically state, if accurate, that it is Davis Polk & Wardwell LLP's opinion that the Domestication will qualify as an F Reorganization for U.S. federal income tax purposes and that the Domestication includes the impacts of the business combination. Describe any factors making it "not possible to predict whether the IRS or a court considering the issue would take a contrary position."

Josh Bayliss
FirstName LastName Josh Bayliss
VG Acquisition Corp.
Company Name VG Acquisition Corp.
April 7, 2021

April 27, 2021 Page 2

Page
FirstName LastName
23andMe's ability to use its net operating loss and research and development credit carryforwards may be subject to limitations, page 40

2. We note your response to comment 7. Please estimate the applicable long-term, tax-exempt rate and describe the applicable additional adjustments.
Business Combination Proposal
The Merger Agreement, page 86

3. We note your response to our prior comment number 8. Please quantify

the value of the
Share Conversion Ratio that is being used as the assumed value
throughout the
registration statement.
Background to the Business Combination, page 91

4. We note your response to our prior comment number 13. Please revise to state, on a
company-by-company basis, why and when discussions ended with the six
potential
candidates mentioned on page 93.
Governing Documents Proposal C - Approval of Other Changes in Connection with
Adoption of
the Proposed Governing Documents, page 122

5. We note your response to our prior comment number 17. Please revise your request that
shareholders approve all other changes necessary or, as mutually
agreed in good faith by
VGAC and 23andMe, desirable in connection with the replacement of the
Existing
Governing Documents with the Proposed Certificate of Incorporation and
Proposed
Bylaws as part of the Domestication to instead make clear that you
are only referring to
immaterial changes and that all material changes are being presented
for a vote.
Information about 23andMe
Overview, page 205

6. We note your response to our prior comment number 19, which we reissue in part: Please
revise the description of the GSK Agreement on page 210 to provide the
following:
the post-termination rights of each party with respect to any of
the 40 drug targets
jointly identified;
duration of any royalty term;
any amounts paid or received to date; and
termination provisions.

Additionally, on page 210 you state that rights extend beyond the
Discovery Term and
may be used for specified other purposes by each party. Please
describe the rights that can
extend beyond the Discovery Term and the purposes for which a party
may use such
rights.

Josh Bayliss
FirstName LastNameJosh Bayliss
VG Acquisition Corp.
Comapany
April NameVG Acquisition Corp.
7, 2021
April 37, 2021 Page 3
Page
FirstName LastName
Our Market Opportunity, page 215

7. We note your response to our prior comment number 23, in which you say you revised
page 223 to include additional information regarding the target
indications identified in
23andMe's preclinical programs. We were unable to locate such
revisions, please revise to
provide information regarding the target indications for the
preclinical programs.
Additionally, with respect to the 40+ early stage programs, we note
that you have
identified 4 therapeutic areas. Please identify your other material
therapeutic areas of
study or delete the reference to "40+." Additionally, provide a
textual discussion of the
current status and activities in each of the material therapeutic
areas.
Intellectual Property, page 224

8. We note your response to our prior comment number 25. Please revise page 224 to
provide the specific products, product groups and technologies to
which such patents

9. Please walk us through a typical consumer service transaction. In your response please address the following:

Tell us how you determined that the initial reports are distinct from the update reports.

Tell us the amount that is allocated to the initial reports versus the update reports in a typical transaction with a consumer. Please tell us how this was determined.

You disclose that update reports are recognized over time where that time period is described as "estimated life of a consumer" which is estimated to be three months for ancestry report updates and twelve months for health report updates. Tell us how you determined the estimated life of a consumer for each report update. In your response tell us how long each customer receives report updates.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.

Josh Bayliss
VG Acquisition Corp.
April 7, 2021
Page 4

You may contact Tara Harkins at 202-551-3639 or Daniel Gordon at 202-551-3486 if you have questions regarding comments on the financial statements and related matters. Please contact Margaret Schwartz at 202-551-7153 or Suzanne Hayes at 202-551-3675 with any other questions.

FirstName LastNameJosh Bayliss
Corporation Finance
Comapany NameVG Acquisition Corp.
Sciences
April 7, 2021 Page 4
cc: Derek Dostal, Esq.
FirstName LastName

Sincerely,
Division of
Office of Life